Average approval time is 7 to 21 days depending on the state
The result of the enlarged chambers is that they cant fill completely resulting in systolic failure
In a major study, the average patient on tirzepatide lost 17.8% of their body weight in one year, whereas the average patient on semaglutide lost 12.4% of their body weight in one year
If results continue to be positive, future steps may include: Pushing toward FDA approval for targeted use cases Developing oral versions to replace intravenous infusions Combining with other muscle-supportive agents like myostatin inhibitors For now, its something to watch, especially if youre someone using GLP-1s and worried about keeping your strength, metabolism, or overall health in check during your weight loss journey
Seems to working at a similar rate as Mounjaro
Many peptides degrade rapidly in the acidic environment of the stomach, but BPC-157 has demonstrated significant resistance to enzymatic breakdown in gastrointestinal models
